Nexalin Technology (NXL) Total Current Liabilities (2021 - 2026)
Nexalin Technology (NXL) recorded quarterly Total Current Liabilities of $808364.0 in Q1 2026, down 8.9% quarter-over-quarter from $887333.0 in Q4 2025, and up 40.65% on a YoY basis from $574736.0 in Q1 2025.
Nexalin Technology (NXL) Total Current Liabilities (2021 - 2026) Analysis & Trends
Nexalin Technology's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $808364.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 40.65% year-over-year to $808364.0; the TTM figure through Mar 2026 stood at $808364.0 (up 40.65% YoY), while the FY2025 annual figure was $887333.0, up 62.31% from the prior year.
- Total Current Liabilities was $808364.0 for Q1 2026 at Nexalin Technology, down from $887333.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.0 million in Q3 2022 to a low of $212104.0 in Q2 2024.
- Historically, Total Current Liabilities has averaged $848247.6 across 5 years, with a median of $600584.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 82.06% in 2024, then surged 183.16% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $1.9 million in 2022, then sank by 78.18% to $425281.0 in 2023, then increased by 28.55% to $546694.0 in 2024, then soared by 62.31% to $887333.0 in 2025, then declined by 8.9% to $808364.0 in 2026.
- The last three Total Current Liabilities figures came in at $808364.0 (Q1 2026), $887333.0 (Q4 2025), and $357524.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 18.38 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 6.32 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 9.50 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 4.57 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 1.41 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 8.70 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 2.22 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 8.53 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 1.15 Bn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | 808,364.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 808,364.00 |
| Dec 31, 2025 | 887,333.00 |
| Sep 30, 2025 | 357,524.00 |
| Jun 30, 2025 | 600,584.00 |
| Mar 31, 2025 | 574,736.00 |
| Dec 31, 2024 | 546,694.00 |
| Sep 30, 2024 | 299,389.00 |
| Jun 30, 2024 | 212,104.00 |
| Mar 31, 2024 | 507,223.00 |
| Dec 31, 2023 | 425,281.00 |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Sep 30, 2022 | 1.98 Mn |
| Dec 31, 2021 | 2.36 Mn |